Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.850 +0.040 (+0.83%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development ↗

March 22, 2023

Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India.

Via Benzinga

Coya Therapeutics' COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study ↗

March 21, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) recently reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to...

Via Benzinga

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

March 21, 2023

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

Via News Direct

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

March 21, 2023

By Kenneth Adams, Benzinga

Via TheNewswire.com

Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients ↗

March 21, 2023

Via Benzinga

Coya Therapeutics Stock Down 3.79% Since IPO ↗

December 30, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 21, 2023

Via Benzinga

Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET

March 21, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

March 21, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302 ↗

March 20, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited.

Via Benzinga

Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

March 20, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET

March 09, 2023

From Coya Therapeutics, Inc.

Via Business Wire

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?

March 06, 2023

By David Willey, Benzinga

Via TheNewswire.com

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?

March 06, 2023

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?

Via News Direct

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier? ↗

March 03, 2023

Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field.

Via Benzinga

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

February 28, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary...

Via TheNewswire.com

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

February 28, 2023

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

Via News Direct

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas ↗

February 27, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary...

Via Benzinga

Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

February 27, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

February 16, 2023

Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

Via News Direct

Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

February 16, 2023

By Ernest Dela Aglanu, Benzinga

Via TheNewswire.com

Coya Therapeutics' Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments ↗

February 15, 2023

Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available...

Via Benzinga

Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate

February 15, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023

February 02, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

January 27, 2023

During Friday, 24 stocks hit new 52-week lows.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023 ↗

January 26, 2023

Via Benzinga

Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

January 26, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering

January 03, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Opening Day: Coya Goes Public In Last Week Of Quiet Year ↗

December 31, 2022

Coya Therapeutics went public this week, making it the last IPO of the year. Meanwhile, LiveOne announced that Courtside Group filed a registration statement with the SEC for its planned spin-out and...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.